Current status of maintenance treatment for metastatic colorectal cancer and characteristics of population with survival benefit

doi:10.3877/cma.j.issn.2095-3224.2019.01.012

Abstract

Abstract:

Maintenance treatment is the strategy aimed to ensure the quality of life meanwhile improve survival with low toxicity drugs after induction treatment. Several studies showed that maintenance therapy could prolong progression free survival (PFS) of patients with metastatic colorectal cancer, but there is no clear evidence to prove that the maintenance treatment could prolong overall survival (OS). It is not clear that which scheme is optimal for maintenance, what characteristics carried by the patients could get more survival benefit from maintenance treatment. We reviewed the current status of maintenance treatment in metastatic colorectal cancer and explore the population who can benefit from maintenance treatment best.

Key words: Colorectal neoplasms, Prognosis, Maintenance treatment, Survival benefit

Ling Hou, Jing Liu, Yunpeng Liu. Current status of maintenance treatment for metastatic colorectal cancer and characteristics of population with survival benefit[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(01): 63-66.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.01.012

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I01/63

References 33

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA cancer J Clin, 2011, 61(2):69-90.
[2]	Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[3]	De GA, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000, 18(16): 2938-2947.
[4]	Goldberg RM, Daniel J, Sargent RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A north American intergroup trial [J]. J Clin Oncol, 2006, 24(21): 3347-3353.
[5]	Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [J]. J Clin Oncol, 2004, 22(2): 229-237.
[6]	Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J]. The Lancet, 2000, 355(9209): 1041-1047.
[7]	Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(12): 2006-2012.
[8]	Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J]. J Clin Oncol, 2004, 22(1): 23-30.
[9]	Kabbinavar FF, Hambleton J, Mass RD, et al. Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer [J]. Journal of Clinical Oncology, 2005, 23(16): 3706-3712.
[10]	Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phaseⅢstudy [J]. J Clin Oncol, 2008, 26(12): 2013-2019.
[11]	Heinemann V, Von-Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. The Lancet Oncology, 2014, 15(10): 1065-1075.
[12]	Pietrantonio F, Garassino MC, Torri V, et al. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 [J]. Ann Oncol, 2012, 23(10): 2771-2772.
[13]	Koeberle D, Betticher DC, Von-Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phaseⅢnon-inferiority trial (SAKK 41/06) [J]. Ann Oncol, 2015, 26(4): 709-714.
[14]	Yalcin S, Uslu R, Dane F, et al. Bevacizumab＋capecitabine as maintenance therapy after initial bevacizumab＋XELOX treatment in previously untreated patients with metastatic colorectal cancer: phaseⅢ'Stop and Go' study results--a Turkish Oncology Group Trial [J]. Oncology, 2013, 85(6): 328-335.
[15]	Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phaseⅢMACRO TTD study [J]. Oncologist, 2012, 17(1): 15-25.
[16]	Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it?[J]. Onco Targets Ther, 2014, 7: 599-618.
[17]	Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study [J]. J Clin Oncol, 2006, 24(3): 394-400.
[18]	Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study [J]. J Clin Oncol, 2009, 27(34): 5727-5733.
[19]	Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial [J]. The Lancet Oncology, 2014, 15(6): 631-639.
[20]	Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial [J]. The Lancet Oncology, 2015, 16(13): 1355-1369.
[21]	Simkens LHJ, Van-Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group [J]. The Lancet, 2015, 385(9980): 1843-1852.
[22]	Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J]. Lancet Oncol, 2011, 12(7): 642-653.
[23]	Xu RH, Shen L, Li J, et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China [J]. Chin J Cancer, 2016, 35(1): 13.
[24]	Waddell T, Gollins S, Soe W, et al. PhaseⅡstudy of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study [J]. Cancer Chemother Pharmacol, 2011, 67(5): 1111-1117.
[25]	Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety [J]. Ann Oncol, 2016, 27(6): 1074-1081.
[26]	Di-Bartolomeo M, Ciarlo A, Bertolini A, et al. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian trials of medical oncology phase Ⅱ study [J]. Eur J Cancer, 2015, 51(4): 473-481.
[27]	HagAlfonso PG, Benavides M, Ruiz AS, et al. PhaseⅡstudy of first-line mfolfox plus cetuximab (C) for 8 cycles followed by mfolfox plus C or single agent(S/A) C as maintenance therapy in patients (P) with metastatic colorectal cancer (mCRC): the MACRO-2 trial (Spanish Cooperative Group for the treatment of digestive tumors [TTD]) [R]. Ann Oncol, 2014, 25: iv168.
[28]	Hagman H, Frodin JE, Berglund A, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial [J]. Ann Oncol, 2016, 27(1): 140-147.
[29]	Munoz A, Pericay C, Garcia-Giron C, et al. PhaseⅡstudy of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer [J]. Oncol Res, 2013, 21(4): 181-191.
[30]	Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial [J]. The Lancet Oncology, 2015, 16(15): 1493-1505.
[31]	Johnsson A, Hagman H, Frodin JE, et al. A randomized phase Ⅲ trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial [J]. Ann Oncol, 2013, 24(9): 2335-2341.
[32]	Xu W, Gong Y, Kuang M, et al. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis [J]. Clin Drug Investig, 2017, 37(2): 155-165.
[33]	Alexander S, Djordje A, Bert H, et al. Upfront FOLFOXIRI＋bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer [J]. Br J Cancer, 2015,113(6): 872-877.

Please choose a citation manager

Content to export